Society of Hematologic Oncology Annual Meeting (SOHO) | Conference

SOHO Spotlight: Hematologists Share Practice-Informing Insights From the 2025 Annual Meeting

September 10th 2025

Hematology experts highlight the MDS, lymphoma, and myeloma data they were most excited to see at the 2025 SOHO Annual Meeting.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Off-the-Shelf, Fixed-Duration Combination Is Active in Relapsed/Refractory MCL

September 6th 2025

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Loncastuximab Tesirine Plus Glofitamab Shows Early Safety and Efficacy in R/R DLBCL

September 6th 2025

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

Dr Issa on Testing for NPM1 or KMT2A Alterations in AML

September 6th 2025

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Mosunetuzumab Demonstrates High Response Rates in Treatment-Naive MZL

September 5th 2025

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

Orca-T Improves Moderate to Severe cGVHD-Free Survival in Hematologic Malignancies

September 5th 2025

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies

Dr Loghavi on SOC Frontline Testing Approaches in MDS

September 5th 2025

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma

September 5th 2025

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Dr Jagannath on the Potential Role of MRD Testing for Defining "Cure" in Myeloma

September 5th 2025

Sundar Jagannath, MBBS, explores how minimal residual disease could redefine what it means to achieve a "cure" in multiple myeloma.

Dr Palandri on Efforts to Elucidate the Role of Predictive Markers for Ruxolitinib in Myelofibrosis

September 5th 2025

Francesca Palandri, MD, discusses research needed to clarify the role of predictive markers for ruxolitinib response in myelofibrosis.

Ziftomenib With 7+3 Shows Early Promise in Newly Diagnosed NPM1-Mutated/KMT2A-Rearranged AML

September 4th 2025

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Peak CAR T-Cell Expansion Associated With Reduced Relapse Risk Following Brexu-Cel Consolidation in B-ALL

September 4th 2025

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL

September 4th 2025

Zanubrutinib bested acalabrutinib plus venetoclax in terms of PFS in patients with treatment-naive, low-risk CLL.

Meta-Analysis Highlights Efficacy, Safety Benefits With Asciminib in Chronic Myeloid Leukemia

September 4th 2025

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

Venetoclax Plus Azacitidine Fails to Provide OS Advantage in Treatment-Naive, Higher-Risk MDS

September 4th 2025

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

Zanubrutinib Prolongs PFS, Shows Trend Toward Improved OS in MAIC Analysis in CLL

September 4th 2025

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

Olutasidenib Monotherapy Yields Responses in Primary Refractory IDH1-Mutant AML

September 4th 2025

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL

September 9th 2024

Zanubrutinib was associated with lower treatment switching rates vs acalabrutinib and ibrutinib in real-world chronic lymphocytic leukemia.

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

September 7th 2024

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.